肝外表现的HCV我们站在哪里?
1National Research Center, Internal Medicine Department, Center of Excellence for Medical Research, Egypt.
型肝炎病毒 (HCV) 感染经常会通过免疫系统的改变和冷球蛋白血症引起肝外表现 (EHM). 抗病毒治疗是关键,但需要更长的随访时间来评估长期的临床影响.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
背景情况:
- 肝炎C病毒 (HCV) 感染与40-70%的患者的肝外表现 (EHM) 有关.
- 肝炎病毒的淋巴细胞性质,特别是B细胞热带性,会引发免疫学变化,免疫复合体的形成和冷球蛋白血症.
研究的目的:
- 探索HCV相关的肝外表现背后的机制.
- 评估冷球蛋白血症在EHM发展中的作用.
- 评估抗病毒疗法的有效性,以管理EHM.
主要方法:
- 审查关于HCV,EHM和冷球蛋白血症的现有文献.
- 对参与HCV病变的免疫路径的分析.
- 对干扰素和直接作用抗病毒药物之间的治疗结果的比较.
主要成果:
- 低血球蛋白血症是许多与HCV相关的EHM的主要驱动因素,如血管炎,血球炎,关节炎和神经病变.
- 直接的病毒细胞病变影响也可以导致EHMs,独立于水晶球蛋白血症.
- 抗病毒疗法,从干扰素到直接作用的抗病毒药物,是EHM的主要治疗方法,尽管病毒学反应率不同,但具有相似的临床疗效.
结论:
- 与HCV相关的EHM源于免疫失调和冷球蛋白血症,直接的病毒影响较少见.
- 抗病毒治疗是控制HCV及其相关EHM的基石.
- 长期的临床评估和随访对于充分了解治疗有效性和疾病进展至关重要.
更多相关视频
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
11:28Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
相关概念视频
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Chronic Kidney Disease II: Clinical Manifestations
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Endocarditis II: Clinical Features of Infective Endocarditis
Nephrotic Syndrome II : Assessment and Medical Management
